{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:38Z","timestamp":1790913638680,"version":"4.1.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["HT9425-23-1-0084"],"award-info":[{"award-number":["HT9425-23-1-0084"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R35-CA231996"],"award-info":[{"award-number":["R35-CA231996"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA244931"],"award-info":[{"award-number":["R01-CA244931"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R37-CA237421"],"award-info":[{"award-number":["R37-CA237421"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["F30CA288093"],"award-info":[{"award-number":["F30CA288093"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01-CA248160"],"award-info":[{"award-number":["R01-CA248160"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009863","name":"Neuroendocrine Tumor Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009863","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000011","name":"Howard Hughes Medical Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000011","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32-GM145470"],"award-info":[{"award-number":["5T32-GM145470"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM00786"],"award-info":[{"award-number":["T32GM00786"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.xcrm.2026.102695","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:49:29Z","timestamp":1774363769000},"page":"102695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors"],"prefix":"10.1016","volume":"7","author":[{"given":"Yizhi","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N.","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somnath","family":"Mahapatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radha","family":"Paturu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrej","family":"Coleski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"VanAken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcya","family":"Pakkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupam","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie J.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuhong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Mannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chungen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaibhav","family":"Sahai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Costas A.","family":"Lyssiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-3415","authenticated-orcid":false,"given":"Arul M.","family":"Chinnaiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.102695_bib1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102695_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.24750","article-title":"Epidemiologic Trends of and Factors Associated With Overall Survival for Patients With Gastroenteropancreatic Neuroendocrine Tumors in the United States","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.xcrm.2026.102695_bib3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/jamaoncol.2019.4568","article-title":"Neuroendocrine Tumors-Less Well Known, Often Misunderstood, and Rapidly Growing in Incidence","volume":"6","author":"Chauhan","year":"2020","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.102695_bib4","first-page":"471","article-title":"Gastroenteropancreatic Neuroendocrine Tumors","volume":"68","author":"Cives","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.102695_bib5","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41416-023-02462-0","article-title":"Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"129","author":"Morken","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.102695_bib6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41392-023-01608-z","article-title":"Multifaceted role of mTOR (mammalian target of rapamycin) signaling pathway in human health and disease","volume":"8","author":"Panwar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.xcrm.2026.102695_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/s41580-019-0199-y","article-title":"mTOR at the nexus of nutrition, growth, ageing and disease","volume":"21","author":"Liu","year":"2020","journal-title":"Nat Rev Mol Cell Bio"},{"key":"10.1016\/j.xcrm.2026.102695_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.xcrm.2026.102695_bib9","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.cmet.2008.07.007","article-title":"SREBP activity is regulated by mTORC1 and contributes to Akt-dependent cell growth","volume":"8","author":"Porstmann","year":"2008","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102695_bib10","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1038\/onc.2009.352","article-title":"Common corruption of the mTOR signaling network in human tumors","volume":"27","author":"Menon","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.xcrm.2026.102695_bib11","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/1078-0432.CCR-09-1314","article-title":"Everolimus","volume":"16","author":"Houghton","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102695_bib12","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for Advanced Pancreatic Neuroendocrine Tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102695_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102695_bib14","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102695_bib15","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.102695_bib16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2015.06.017","article-title":"The Utilization of Extracellular Proteins as Nutrients Is Suppressed by mTORC1","volume":"162","author":"Palm","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib17","doi-asserted-by":"crossref","first-page":"8023","DOI":"10.1074\/jbc.M900301200","article-title":"An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1","volume":"284","author":"Thoreen","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102695_bib18","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/s43018-021-00237-1","article-title":"Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer","volume":"2","author":"Qiao","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.xcrm.2026.102695_bib19","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.3324\/haematol.2019.222729","article-title":"Identification of PIKfyve kinase as a target in multiple myeloma","volume":"105","author":"de Campos","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.xcrm.2026.102695_bib20","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2314416120","article-title":"Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy","volume":"120","author":"Bao","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102695_bib21","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41586-025-08917-z","article-title":"Targeting PIKfyve-driven lipid metabolism in pancreatic cancer","volume":"642","author":"Cheng","year":"2025","journal-title":"Nature"},{"key":"10.1016\/j.xcrm.2026.102695_bib22","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1158\/1078-0432.CCR-19-4042","article-title":"A Randomized Phase II Preoperative Study of Autophagy Inhibition with High-Dose Hydroxychloroquine and Gemcitabine\/Nab-Paclitaxel in Pancreatic Cancer Patients","volume":"26","author":"Zeh","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102695_bib23","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.3545","article-title":"Phase II trial of the autophagy inhibitor hydroxychloroquine with FOLFOX and bevacizumab in front line treatment of metastatic colorectal cancer","volume":"35","author":"O'Hara","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.102695_bib24","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1093\/jac\/dkv018","article-title":"Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases","volume":"70","author":"Al-Bari","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.xcrm.2026.102695_bib25","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.devcel.2021.05.010","article-title":"Glucose starvation induces autophagy via ULK1-mediated activation of PIKfyve in an AMPK-dependent manner","volume":"56","author":"Karabiyik","year":"2021","journal-title":"Dev. Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib26","doi-asserted-by":"crossref","first-page":"37321","DOI":"10.1074\/jbc.M605241200","article-title":"Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth","volume":"281","author":"Gan","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102695_bib27","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/nrc3792","article-title":"FAK in cancer: mechanistic findings and clinical applications","volume":"14","author":"Sulzmaier","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102695_bib28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrc1524","article-title":"Integrin-linked kinase: a cancer therapeutic target unique among its ILK","volume":"5","author":"Hannigan","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xcrm.2026.102695_bib29","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-24-1757","article-title":"Concurrent Inhibition of the RAS-MAPK Pathway and PIKfyve is a Therapeutic Strategy for Pancreatic Cancer","volume":"85","author":"DeLiberty","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102695_bib30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s10637-024-01482-8","article-title":"Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer","volume":"42","author":"Heath","year":"2024","journal-title":"Invest New Drug"},{"key":"10.1016\/j.xcrm.2026.102695_bib31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1007\/s10637-024-01463-x","article-title":"Phase II trial of multi-kinase inhibitor ESK981 in patients with metastatic castration-resistant prostate cancer","volume":"42","author":"Heath","year":"2024","journal-title":"Invest New Drug"},{"key":"10.1016\/j.xcrm.2026.102695_bib32","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/nrendo.2017.91","article-title":"SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology","volume":"13","author":"Shimano","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.102695_bib33","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.cell.2015.02.019","article-title":"Cholesterol transport through lysosome-peroxisome membrane contacts","volume":"161","author":"Chu","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib34","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cmet.2013.08.002","article-title":"A Central role for mTOR in lipid homeostasis","volume":"18","author":"Lamming","year":"2013","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102695_bib36","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/gutjnl-2021-325117","article-title":"Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer","volume":"72","author":"De Santis","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.xcrm.2026.102695_bib37","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.molcel.2016.09.037","article-title":"An Autophagic Flux Probe that Releases an Internal Control","volume":"64","author":"Kaizuka","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/s41556-019-0391-5","article-title":"ER-lysosome contacts enable cholesterol sensing by mTORC1 and drive aberrant growth signalling in Niemann-Pick type C","volume":"21","author":"Lim","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102695_bib39","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2016.12.034","article-title":"A Red Carpet for Iron Metabolism","volume":"168","author":"Muckenthaler","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib40","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1128\/MCB.01437-10","article-title":"Distinct mechanisms of ferritin delivery to lysosomes in iron-depleted and iron-replete cells","volume":"31","author":"Asano","year":"2011","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102695_bib41","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.cmet.2012.10.001","article-title":"mTOR regulates cellular iron homeostasis through tristetraprolin","volume":"16","author":"Bayeva","year":"2012","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102695_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.fct.2022.112909","article-title":"Ferritinophagy is involved in Bisphenol A-induced ferroptosis of renal tubular epithelial cells through the activation of the AMPK-mTOR-ULK1 pathway","volume":"163","author":"Bao","year":"2022","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.xcrm.2026.102695_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/84859","article-title":"Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice","volume":"27","author":"LaVaute","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.xcrm.2026.102695_bib44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00018-025-05695-9","article-title":"Muscle mTOR controls iron homeostasis and ferritinophagy via NRF2, HIFs and AKT\/PKB signaling pathways","volume":"82","author":"Conjard-Duplany","year":"2025","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.xcrm.2026.102695_bib45","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cmet.2015.12.005","article-title":"Disease-Causing SDHAF1 Mutations Impair Transfer of Fe-S Clusters to SDHB","volume":"23","author":"Maio","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.xcrm.2026.102695_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adf9284","article-title":"Autophagy supports mitochondrial metabolism through the regulation of iron homeostasis in pancreatic cancer","volume":"9","author":"Mukhopadhyay","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.xcrm.2026.102695_bib47","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11912-021-01029-7","article-title":"Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences?","volume":"23","author":"Das","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.xcrm.2026.102695_bib48","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41574-020-00458-x","article-title":"Diagnostic and therapeutic advances in neuroendocrine tumours","volume":"17","author":"Caplin","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.xcrm.2026.102695_bib49","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.xcrm.2026.102695_bib50","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41580-023-00585-z","article-title":"Autophagy and autophagy-related pathways in cancer","volume":"24","author":"Debnath","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.xcrm.2026.102695_bib51","doi-asserted-by":"crossref","first-page":"12297","DOI":"10.1074\/jbc.M900573200","article-title":"ULK1.ATG13.FIP200 complex mediates mTOR signaling and is essential for autophagy","volume":"284","author":"Ganley","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.xcrm.2026.102695_bib52","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.cell.2012.12.016","article-title":"Differential regulation of distinct Vps34 complexes by AMPK in nutrient stress and autophagy","volume":"152","author":"Kim","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib53","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.4161\/auto.26058","article-title":"Regulation of PIK3C3\/VPS34 complexes by MTOR in nutrient stress-induced autophagy","volume":"9","author":"Yuan","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.xcrm.2026.102695_bib54","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.molcel.2017.01.027","article-title":"Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy","volume":"65","author":"Qian","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2026.102695_bib55","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1158\/1535-7163.MCT-17-0136","article-title":"Autophagy Inhibition Improves Sunitinib Efficacy in Pancreatic Neuroendocrine Tumors via a Lysosome-dependent Mechanism","volume":"16","author":"Wiedmer","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.xcrm.2026.102695_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102661","article-title":"Cholesterol confers ferroptosis resistance onto myeloid-biased hematopoietic stem cells and prevents irradiation-induced myelosuppression","volume":"62","author":"Liu","year":"2023","journal-title":"Redox Biol."},{"key":"10.1016\/j.xcrm.2026.102695_bib57","doi-asserted-by":"crossref","first-page":"19507","DOI":"10.1073\/pnas.1318431110","article-title":"Bioavailable copper modulates oxidative phosphorylation and growth of tumors","volume":"110","author":"Ishida","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.xcrm.2026.102695_bib58","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.tibs.2021.07.003","article-title":"The lysosome as a master regulator of iron metabolism","volume":"46","author":"Rizzollo","year":"2021","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/j.xcrm.2026.102695_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adk1731","article-title":"Targeting ferritinophagy impairs quiescent cancer stem cells in acute myeloid leukemia in vitro and in vivo models","volume":"16","author":"Larrue","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.102695_bib60","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1158\/1078-0432.CCR-18-2204","article-title":"Autophagy Inhibition to Augment mTOR Inhibition: a Phase I\/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma","volume":"25","author":"Haas","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.102695_bib61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1530\/EC-18-0397","article-title":"Apatinib inhibits tumor growth and angiogenesis in PNET models","volume":"8","author":"Wu","year":"2019","journal-title":"Endocr. Connect."},{"key":"10.1016\/j.xcrm.2026.102695_bib62","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1158\/2159-8290.CD-22-0043","article-title":"NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron-Sulfur Cluster Proteins","volume":"12","author":"Santana-Codina","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102695_bib63","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.xcrm.2026.102695_bib64","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.gpb.2022.01.004","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets","volume":"20","author":"Zheng","year":"2022","journal-title":"Genom. Proteom. Bioinform."},{"key":"10.1016\/j.xcrm.2026.102695_bib65","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1158\/2159-8290.CD-22-0044","article-title":"Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS-MAPK Pathway Inhibition in Pancreatic Cancer","volume":"12","author":"Ravichandran","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.xcrm.2026.102695_bib66","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001126?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126001126?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:23:34Z","timestamp":1778919814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126001126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2666379126001126"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102695","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.102695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102695"}}